SalaryGuide
AboutPricingFor Employers

Marketing jobs

29 marketing jobs

AstraZeneca logo
4 months ago

Executive Director, Marketing (R&I)

AstraZeneca

Wilmington, DE (Unknown)Full time
AstraZeneca logo
4 months ago

Executive Director, Marketing (R&I)

AstraZeneca

Wilmington, DE (Hybrid)Full time
AstraZeneca logo
4 months ago

CRM Activation Tech Lead, U.S. BioPharmaceuticals Customer Engagement

AstraZeneca

Wilmington, DE (On-site)Full time
AstraZeneca logo
4 months ago

Global Brand Director LCM - R&I

AstraZeneca

Gaithersburg, MD (Hybrid)Full time$232K/yr – $348K/yr
AstraZeneca logo
4 months ago

Brand Manager, US Marketing

AstraZeneca

Wilmington, DE (On-site)Full time
AstraZeneca logo
4 months ago

Marketing Director, US Marketing

AstraZeneca

Wilmington, DE (On-site)Full time
AstraZeneca logo
4 months ago

Director - Science Communications and Engagement, Late CVRM

AstraZeneca

Gaithersburg, MD (On-site)Full time$147K/yr – $220K/yr
AstraZeneca logo
4 months ago

Global Marketing Director, CVRM

AstraZeneca

Boston, MA (On-site)Full time$229K/yr – $344K/yr
AstraZeneca logo
5 months ago

Activation Tech Lead, U.S. BioPharmaceuticals Customer Engagement

AstraZeneca

Wilmington, DE (On-site)Full time
Previous
12
Next

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

29 jobs
AstraZeneca logo

Executive Director, Marketing (R&I)

AstraZeneca

Wilmington, DE (Unknown)

In-houseFull-timeSenior level10+ years exp.
4 months ago
AstraZeneca logo

Executive Director, Marketing (R&I)

AstraZeneca

Wilmington, DE (Hybrid)

In-houseFull-timeSenior level10+ years exp.
4 months ago
AstraZeneca logo

CRM Activation Tech Lead, U.S. BioPharmaceuticals Customer Engagement

AstraZeneca

Wilmington, DE (On-site)

In-houseFull-timeSenior level5+ years exp.
4 months ago
AstraZeneca logo

Global Brand Director LCM - R&I

AstraZeneca

Gaithersburg, MD (Hybrid)

$232K/yr - $348K/yrIn-houseFull-timeSenior level
4 months ago
AstraZeneca logo

Brand Manager, US Marketing

AstraZeneca

Wilmington, DE (On-site)

In-houseFull-timeMid level3+ years exp.
4 months ago
AstraZeneca logo

Marketing Director, US Marketing

AstraZeneca

Wilmington, DE (On-site)

In-houseFull-timeDirector/executive6+ years exp.
4 months ago
AstraZeneca logo

Director - Science Communications and Engagement, Late CVRM

AstraZeneca

Gaithersburg, MD (On-site)

$147K/yr - $220K/yrIn-houseFull-timeDirector/executive5+ years exp.
4 months ago
AstraZeneca logo

Global Marketing Director, CVRM

AstraZeneca

Boston, MA (On-site)

$229K/yr - $344K/yrIn-houseFull-timeDirector/executive10+ years exp.
4 months ago
AstraZeneca logo

Activation Tech Lead, U.S. BioPharmaceuticals Customer Engagement

AstraZeneca

Wilmington, DE (On-site)

In-houseFull-timeSenior level5+ years exp.
5 months ago
Previous12
AstraZeneca logo
AstraZeneca

Executive Director, Marketing (R&I)

Wilmington, DE (Unknown)

Salary Not AvailableSenior Level10+ years expFull time

Posted 4 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Drive global AstraZeneca R&I marketing strategy and launch readiness as Executive Director, Marketing, leading brand strategy, cross-functional execution, and TA lifecycle planning.

  • Own the asset's launch strategy, pre-launch plans, and cross-functional execution.
  • Must-have: 10+ years in pharma/biotech with US product launches.
  • Standout: leads cross-functional teams and partners with Sales to align strategy and forecast.

Job Description

Responsibilities

  • Build bold brand ambition to improve patient impact based on deep insight from external Scientific Experts (ESEs), Payers, Patients, advocacy organizations and other key partners.
  • Develop detailed product strategy and promotional campaign for the asset including pre-launch and launch strategy and operational plans.
  • P&L ownership including forecast development and performance v forecast.
  • Own the execution of the marketing plans, driving innovation and implementing key marketing initiatives while embracing new channels (e.g., omnichannel) and technology (AI).
  • Inform the brand strategic decisions – including life cycle planning and data generation - in line with longer term objectives, relevance for patients, customers, and market.
  • Partner with Sales leadership to ensure organizational alignment from strategy through field execution. Set brand strategies for the sales organization and hold sales leaders accountable to performance and forecast delivery.
  • Collaborate and maintain positive relationships with strategic partners globally and in the US.
  • Actively participate in R&I Leadership Team – participating and leading TA initiatives to optimize the value of the portfolio and strengthen the skills of the team.
  • Build an employee experience that ignites innovation and unites talent to deliver the business. Lead and align team around a clear vision and purpose.

Requirements

  • Bachelor's Degree, preferably in business, marketing, or the sciences.
  • 10 years’ experience in pharmaceutical, healthcare or biotech industries
  • Consistent track record leading successful development of brand and/or TA strategies, which are founded on clear customer and market insights.
  • US Product launch experience
  • Experience in and/or leading customer facing roles.
  • Experience using clinical data in crafting brand strategies and lifecycle planning.
  • Successful experience in leading and developing strong performing teams, partner engagement, and the ability to work cross functionally to move key initiatives forward.

Preferred

  • Experience with revenue forecasting, expense management, developing compelling business reasons and management/communication of brand performance.
  • Strong knowledge of US R&I thought leaders.
  • Ability to identify innovative strategies with the greatest business impact and empower their teams to implement the plan.
  • Strong curiosity, growth mindset and high learning agility
AstraZeneca logo

AstraZeneca

4.0 Glassdoor

We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com.Community Guidelines: bit.ly/2MgAcio

Founded in 1999
Cambridge, England, GBR
77K employees (4,201 in marketing)
www.astrazeneca.com
78% recommend to a friend
89% CEO approval

Traffic Signals

Monthly Visitors
1.3M
Monthly Google Ads Budget
$3.7K
Traffic Source Mix
Search
45.1%
Direct
42%
Referral
9.3%
Social
2.6%
Paid
0.9%

Headcount Trend

Current headcount: ~76.8K

Marketing Team

Marketing Team Size
3,642 (5% of company)
Median Career Experience
15 years
Median Tenure
5.3 years
Marketing Roles Posted (Last 30 Days)
18

People

Marketing Leadership

Nadia Al-Aydi
Nadia Al-Aydi
Head US Marketing, Oncology Business Unit, AstraZeneca Pharmaceuticals
At the company for 2 years 1 month
Stephen Borboroglu
Stephen Borboroglu
Global Head of Marketing, baxdrostat / dapagliflozin
At the company for 5 years 11 months
Robert Hillman
Robert Hillman
Head of US Marketing Immunology
At the company for 2 years 4 months
Mike Hill
Mike Hill
Global Head of Marketing & Market Access | Oncology Diagnostics
At the company for 2 years 10 months

Funding

Total Funding
$7.3B
Last Raise
$2B
Post IPO Debt, 19 days ago

Funding History

  • Feb 2026
    Post IPO Debt • $2B
  • Jul 2024
    Post IPO Debt • $1.5B
  • Feb 2023
    Post IPO Debt • $2.3B

Recent News

AstraZeneca makes deal with Trump to lower drug prices and avoid tariffs
Oct 11, 2025 • The Guardian
AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump
Oct 9, 2025 • Reuters
AstraZeneca blood pressure drug succeeds in late-stage trial
Oct 7, 2025 • Financial Times
AstraZeneca threatens to stop investing in Britain
Oct 6, 2025 • The Telegraph
AstraZeneca signs up to $555 million AI deal with Algen to develop therapies
Oct 6, 2025 • Reuters
AstraZeneca signs $555mn AI deal to identify immunology targets
Oct 6, 2025 • Financial Times
AstraZeneca’s US listing to leave £200mn UK stamp duty hole
Oct 2, 2025 • Financial Times
AstraZeneca to elevate New York listing in blow to London
Sep 29, 2025 • Financial Times
AstraZeneca to upgrade US listing in ‘knock-back for London’
Sep 29, 2025 • The Guardian
AstraZeneca plots US stock listing amid industry pullback from Britain
Sep 29, 2025 • Fierce Pharma
'Knock-back for London' as AstraZeneca sells shares directly on rival New York Stock Exchange
Sep 29, 2025 • Sky News
AstraZeneca Revamps NYSE Listing To Woo US Investors
Sep 29, 2025 • Law360
FTSE 100 Live 29 September: Index nears record, GSK shares rise on CEO change
Sep 29, 2025 • London Evening Standard
AstraZeneca to List Shares Directly on New York Stock Exchange -- Update
Sep 29, 2025 • MarketScreener
Trending tickers: Alibaba, AstraZeneca, GSK, Stellantis and Genmab
Sep 29, 2025 • Yahoo Finance - Business Finance, Stock Market, Quotes, News
AstraZeneca's Board Proposes Harmonized Listing Structure
Sep 29, 2025 • MarketScreener
U.S. Pharma Tariff a 'Significant Concern' to Singapore, Says Top Official
Sep 29, 2025 • MarketScreener
AstraZeneca to harmonize global listing structure
Sep 29, 2025 • thefly.com
AstraZeneca shares soar as it confirms dual UK-US stockmarket listing
Sep 29, 2025 • businessweekly.co.uk
GSK commercial chief to become CEO at start of "pivotal" 2026
Sep 29, 2025 • MarketScreener
Fresh US tariffs rock AstraZeneca and GSK
Sep 27, 2025 • Markets | Mail Online
Pharma firms still keen to grow in S’pore but investment climate will get more competitive: DPM Gan
Sep 27, 2025 • Straits Times
3 Magnificent Stocks Under $100 to Buy Right Now
Sep 27, 2025 • The Motley Fool
AstraZeneca loses crown as UK’s most valuable company
Sep 26, 2025 • The Telegraph
Astrazeneca to Launch Direct-to-Consumer Platform on Oct. 1
Sep 26, 2025 • MarketScreener
European pharma shares drop after Trump threatens more tariffs
Sep 26, 2025 • Investing.com
Global drugmakers rush to boost US presence as tariff threat looms
Sep 26, 2025 • Reuters
Trump announces new tariffs on pharmaceuticals from October
Sep 26, 2025 • Irish Times
Trump’s drug tariffs are days away. Massachusetts’ pharma companies aren’t worried.
Sep 26, 2025 • Boston Globe
Trump announces 100% tariffs on pharmaceuticals unless drug makers are building U.S. factories
Sep 26, 2025 • Morningstar.com
Trump slaps 100 per cent tariff on imported drugs
Sep 26, 2025 • City A.M.
Eli Lilly’s boss calls UK the ’worst’ European country for drug prices
Sep 24, 2025 • Investing.com
Stocks lower after Trump u-turn on Ukraine
Sep 24, 2025 • MarketScreener
Burning Rock's Sequencing Test Approved in Japan as a CDx for Truqap in Breast Cancer
Sep 24, 2025 • GenomeWeb
Daiichi Sankyo and AstraZeneca's Supplemental Biologics License Application for Enhertu®? in Combination with Pertuzumab Deruxtecan-nxki
Sep 24, 2025 • MarketScreener
Hood College Receives NSF Grant for Biotechnology Training Program
Sep 24, 2025 • PR Newswire
Eli Lilly's boss calls UK the 'worst' European country for drug prices
Sep 24, 2025 • Reuters
Mounjaro manufacturer blasts UK as ‘worst country in Europe’ for drug prices
Sep 24, 2025 • The Independent
ENHERTU® Plus Pertuzumab Granted Priority Review in the U.S. as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
Sep 24, 2025 • BioSpace
United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO
Sep 24, 2025 • Benzinga.com
AstraZeneca and Daiichi's breast cancer drug wins US priority review
Sep 24, 2025 • MarketScreener
Roche's oral SERD comes good in 2nd-line breast cancer trial
Sep 23, 2025 • pharmaphorum
Global Preventive Healthcare Technologies & Services Market to Reach USD 773.1 Billion by 2034 at 10.6% CAGR | TMR
Sep 23, 2025 • EIN Presswire
Economist Impact's 5th edition Future of Health Asia returns to Singapore amid rising technological disruption, chronic disease burdens and international trade tensions
Sep 23, 2025 • PR Newswire UK
BMS says it will set Cobenfy's UK price the same as the US
Sep 23, 2025 • pharmaphorum
DaltonTx raises £4 million seed financing to build the intelligence backbone of drug discovery
Sep 23, 2025 • PR Newswire UK
ADC Innovator Myricx Bio Appoints Boston-based Mohit Rawat as CEO and Expands Team in US and UK
Sep 23, 2025 • PharmiWeb
AstraZeneca delivering on many fronts with next-generation propellant
Sep 23, 2025 • Pharma Letter
ADC Innovator Myricx Bio Appoints Boston-based Mohit Rawat as CEO and Expands Team in US and UK
Sep 22, 2025 • Myricx Bio
FTSE 100 Closes Higher; AstraZeneca Gains
Sep 22, 2025 • MarketScreener
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
Sep 22, 2025 • prnasia.com
ALEX BRUMMER: Donald Trump's big pharma win
Sep 20, 2025 • Markets | Mail Online
AstraZeneca presents conclusive results against neuromyelitis optica
Sep 19, 2025 • MarketScreener
AstraZeneca says Ultomiris shows 3 years relapse-free in NMOSD
Sep 19, 2025 • MarketScreener
Kuehn Law Encourages Investors of Tempus AI, Inc. to Contact Law Firm
Sep 19, 2025 • PR Newswire
Opinion: STAT+: Why pharma companies are suddenly pausing investment in the U.K.
Sep 19, 2025 • STAT
Kuehn Law Encourages Investors of Tempus AI, Inc. to Contact Law Firm
Sep 19, 2025 • Morningstar.com
Polish healthtech startup Doctor.One raises €4M seed round to expand across Europe
Sep 19, 2025 • ain.ua
Wary pharma: AstraZeneca sours on UK
Sep 18, 2025 • The Economist
Top 10 VC and PE in Europe: Meet the Performance Leaders
Sep 18, 2025 • Silicon Canals
Roivant, Pfizer’s Therapy Shows ‘Patient-Centered Benefit’ in Rare Inflammatory Condition
Sep 18, 2025 • BioSpace
The Myositis Association Celebrates World Myositis Day 2025 with Global Events and Special Keynote
Sep 18, 2025 • EIN Presswire
Big Pharma’s pullback from the UK could have serious side-effects for Ireland
Sep 18, 2025 • Irish Times
AstraZeneca says Saphnelo met primary endpoint in Tulip-SC
Sep 17, 2025 • MarketScreener
AstraZeneca's Fasenra Fails to Meet Primary Endpoint in Pulmonary Disease Trial
Sep 17, 2025 • MarketScreener
AstraZeneca fails to meet primary endpoint in Phase III trial
Sep 17, 2025 • MarketScreener
AstraZeneca's asthma drug fails main goal of COPD study
Sep 17, 2025 • MarketScreener
AstraZeneca says Fasenra misses main goal in COPD trial
Sep 17, 2025 • Investing.com
AstraZeneca's asthma drug fails 'smoker's lung' study
Sep 17, 2025 • IndiaTimes
AstraZeneca plc Announces Saphnelo Met Primary Endpoint in TULIP-SC
Sep 17, 2025 • MarketScreener
AZ's bid for Fasenra approval in COPD falls short
Sep 17, 2025 • pharmaphorum
AstraZeneca's asthma drug fails main goal of COPD study
Sep 17, 2025 • MarketScreener
Drugmakers have pledged to invest $350 billion in US after tariff threat
Sep 17, 2025 • Livemint.com
AstraZeneca president says UK is 'increasingly challenging'
Sep 16, 2025 • BBC
AstraZeneca Pauses Plans for $271 Million Expansion of U.K. Site
Sep 15, 2025 • The Wall Street Journal
AstraZeneca shares down 3% after rating cut, UK investment pause
Sep 15, 2025 • Reuters
Global Pharma 5.0 Market to Reach $98.68 Billion at a Steady 6% CAGR by 2029
Sep 15, 2025 • EIN Presswire
CEO and FD ousted from board of listed MedTech
Sep 14, 2025 • BusinessCloud
AZ halts UK investment, and Lilly, Sanofi follow suit
Sep 14, 2025 • pharmaphorum
3 Emerging Tech Stocks That Could Help Set You Up for Life
Sep 14, 2025 • The Motley Fool
Britain’s biggest company AstraZeneca pauses £200m investment into Cambridge site
Sep 13, 2025 • The Independent
Astrazeneca pauses £200m Cambridge investment
Sep 13, 2025 • City A.M.
AstraZeneca's £200m blow to Labour as pharma giant scraps major investment
Sep 13, 2025 • Markets | Mail Online
Radioligand Therapy (RLT) Market worth US$10.9 billion by 2035 with 13.2% CAGR | MarketsandMarkets™
Sep 13, 2025 • PR Newswire
AstraZeneca pauses £200m Cambridge expansion amid NHS pricing row
Sep 12, 2025 • The Telegraph
AstraZeneca pauses £200m Cambridge investment
Sep 12, 2025 • BBC
AstraZeneca pauses £200m expansion in Cambridge
Sep 12, 2025 • Yahoo
AstraZeneca pauses £200m investment in Cambridge research site
Sep 12, 2025 • The Guardian
Exclusive: AstraZeneca pauses $270 million investment in Britain
Sep 12, 2025 • Reuters
AstraZeneca Pauses £200 Million Investment in UK Headquarters
Sep 12, 2025 • Bloomberg.com
AstraZeneca pauses $271M expansion in UK—the latest Big Pharma to buck Britain
Sep 12, 2025 • Fierce Biotech
Pharma Industry Weighs Where to Hold Its IP Amid Tariff Turmoil
Sep 12, 2025 • bloomberglaw.com
AstraZeneca Pauses $271 Million Cambridge Project
Sep 12, 2025 • MarketScreener
Lupus Reveal Gives Investors a Peek at Biogen’s ‘Underappreciated’ Pipeline
Sep 9, 2025 • BioSpace
Kling Bio Validates its Proprietary B-Cell Technology for Rapid Response Against Emerging Viral Variants
Sep 9, 2025 • PR Newswire
With Asthma-Related ER Visits Increasing, AAFA Names 2025 Asthma Capitals
Sep 9, 2025 • Morningstar.com
BizClik Announces the Top 250 Companies in Sustainability for 2025
Sep 9, 2025 • PR Newswire UK
Lannebo Mixfond Rises 0.6% in August - Novonesis and Indutrade Added to Portfolio
Sep 9, 2025 • MarketScreener
BizClik Announces the Top 250 Companies in Sustainability for 2025
Sep 9, 2025 • PR Newswire
Tive Partners with AstraZeneca to Provide a Temperature Tracker for FluMist Home Delivery Program
Sep 9, 2025 • Tive, Inc.